20.2 C
New York
Saturday, September 23, 2023
- Advertisement -

    World-first breakthrough for breast cancer

    Hong Kong – Chemists at the Hong Kong Baptist University (HKBU) have discovered the use of a metal compound that inhibits the enzyme closely associated with triple-negative breast cancer (TNBC), one of the most challenging forms of breast cancer to treat.

    The metal compound has been found to inhibit TNBC tumours with less toxicity in mice. Their work has also further unmasked the role of the enzyme, lysine-specific demythylase 5A (KDM5A), in TNBC. The reported compound shows tremendous potential for the development of drugs for TNBC therapy. The results of this study were published in the leading chemistry journal Angewandte Chemie International Edition.

    The team led by Dr. Edmond Ma Dik-lung, Associate Professor of HKBU’s Department of Chemistry had developed the compound using a metal named rhodium as a direct, potent and selective inhibitor of KDM5A; in other words, the compound can effectively target KDM5A which is a key limitation of existing KDM5A inhibitors.

    Dr. Ma said that KDM5A is overexpressed in breast cancer and other human cancers, including brain, lung and gastric cancers, thus, promoting carcinogenesis and drug resistance. At present, only a few KDM5A inhibitors have been reported, but most of them cannot effectively detect KDM5A, limiting their ability to inhibit it.

    “The compound acts by disrupting the interaction between KDM5A and trimethylated histone H3, a protein that regulates the folding of DNA. This leads to the accumulation of methylated marks on histone H3, which in turn increases the expression of p27, a protein that suppresses tumour growth. The compound was found to be capable of suppressing cells’ growth process in TNBC cell lines and demonstrated potent anti-tumour activity against TNBC in an in vivo mouse model. It is also important to note that the new compound was less toxic in vivo compared with two well-known clinical anti-cancer drugs, cisplatin and doxorubicin”, said Dr. Ma.

    “The traditional TNBC treatments are limited by drug resistance and serious side effects, including organ damage. Therefore, there is an urgent need to develop new targeted approaches for the treatment of TNBC. We therefore believe that our metal compound shows great promise for the development of targeted drugs for TNBC therapy”, Dr. Ma pointed out.

    The research project titled “Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium complex for triple-negative breast cancer therapy”, was led by Dr. Ma and Professor Leung Chung-hang of the Institute of Chinese Medical Sciences, University of Macau. Other collaborators in the project include researchers from the Macau University of Science and Technology, the City University of Hong Kong, and Jiangsu Normal University, China.